Teva again raises guidance as branded drugs lift revenue...

Economics and markets | Nov 3, 2026, 1:39 PM

Teva Pharmaceutical Industries reported third-quarter revenue of $4.4 billion, exceeding analyst expectations of $4.2 billion.

The company posted non-GAAP earnings per share of $0.86, above the consensus of $0.72, and raised its guidance again on strength from branded drugs.

PRO: see who's reacting and what you're missing. See the whole picture →